psoriasis drug Tremfya. Johnson and Johnson is on track to become a $100 billion company this year - and it just got closer. The healthcare giant beat Q1 estimates on both revenue and profit before raising its full-year sales forecast. Revenue came in at $24.1 billion - up nearly 10% from a year ago - topping the $23.6 billion consensus, while adjusted earnings hit $2.70 per share above the $2.66 estimate.
J&J's drug business jumped 11.2% to $15.4 billion, powered by two standout performers: Darzalex, a cancer treatment, and Tremfya, which treats psoriasis. Those gains more than offset a steep drop in sales of Stelara - J&J's former blockbuster that's now facing cheaper competition.
J&J now expects 2026 revenue between $100.3 billion and $101.3 billion, with a midpoint of $100.8 billion that sits slightly above what analysts had modeled. Adjusted earnings per share are projected at $11.45 to $11.65 for the year.
J&J is one of the most widely held stocks among dividend investors and retirement accounts. A strong quarter and a guidance raise from a company this size signals that healthcare spending remains solid - even as the broader economy faces pressure from the war and inflation.
